+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 75Years
All Genders
ID07367516

Evaluating Safety and Effectiveness of TQB6411 Injection for Recurrent or Metastatic Esophageal Cancer After Prior PD-1PD-L1 and Platinum Chemotherapy Failure

Led by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Updated on 2026-09-15

105

Participants Needed

30

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of TQB6411 Injection in adults with recurrent or metastatic esophageal cancer who have not responded to prior treatment with PD-1PD-L1 inhibitors combined with platinum-based chemotherapy. This study includes both Phase Ib, focusing on safety and tolerance, and Phase II, which assesses how well the treatment works in this patient group. Participants receive TQB6411 Injection in treatment cycles lasting either 21 or 28 days. TQB6411 is an antibody-drug conjugate targeting specific proteins EGFR and c-Met involved in cancer growth. The treatment is given continuously during the study period to evaluate its effects and safety. During the trial, participants will have regular assessments including tumor measurements, blood tests, and monitoring for side effects over a period of up to 24 months. Researchers will measure outcomes such as recommended dose, adverse events, progression-free survival, response rates, and overall survival. Additional tests will evaluate drug concentration in the blood and immune responses to the treatment. Participants will be closely monitored for safety throughout the study duration.

CONDITIONS

Brief Title

Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer

Research Team

F

Feng Wang, Doctor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here